Eisai announced on March 11 that it has concluded a worldwide strategic partnering agreement with Epizyme, Inc. of the US to discover, develop, and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in…
To read the full story
Related Article
- Eisai Transfers Tazemetostat Royalty Rights Outside Japan to US Firm
November 6, 2019
- Eisai Revises Deal with Epizyme on Cancer Therapies
March 13, 2015
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





